Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Nova Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,112,368

567 payments

Through program year 2025, Nova Clinical Research LLC is reported as receiving $1,112,368 in research payments, across 567 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $64,144 26
2024 Research $311,319 28
2023 Research $345,405 42
2022 Research $107,739 7
2021 Research $155,749 449
2020 Research $99,067 10
2019 Research $28,946 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Vertex Pharmaceuticals Incorporated $318,293 5 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $222,549 34 payments
  3. Novartis Pharmaceuticals Corporation $145,269 9 payments
  4. Insmed, Inc. $109,145 56 payments
  5. US WorldMeds, LLC $98,705 441 payments
  6. Akebia Therapeutics Inc $70,567 3 payments
  7. AbbVie, Inc. $58,652 6 payments
  8. Biogen, Inc. $55,310 3 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $12,268 3 payments
  10. ACADIA Pharmaceuticals Inc $10,500 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease $307,217 3 payments
  2. A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact $109,145 56 payments
  3. An observer-blind multi-center placebo-controlled parallel group study to assess the safety and tolerability and to characterize the pharmacokinetics and the pharmacodynamics of different doses of BAY 1213790 in patients with end-stage renal disease undergoing hemodialysis $105,158 13 payments
  4. A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of Myobloc in the Treatment of Adult Lower Limb Spasticity Followed By An Open-Label Extension, Multiple-Treatment Safety Study of Myobloc $72,756 433 payments
  5. A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects $70,567 3 payments
  6. Osocimab in ESRD Phase 2b study $63,416 10 payments
  7. A Randomized, Controlled, Multicenter, Open-Label Trial Comparing A Post-Discharge Care Pathway Involving Aggressive LDL-C Management With Inclisiran With Usual Care in Patients With A Recent Acute Coronary Syndrome $52,815 1 payment
  8. A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $45,966 1 payment
  9. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $43,902 5 payments
  10. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $35,156 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record